NOT-HG-23-013: Notice of Early Expiration of RFA-HG-21-001, Technology Development for Single-Molecule Protein Sequencing (R01 Clinical Trial Not Allowed)" & RFA-HG-21-002, Technology Development for Single-Molecule Protein Sequencing (R21 Clinical Trial Not Allowed)"

Notice of Early Expiration of RFA-HG-21-001, “Technology Development for Single-Molecule Protein Sequencing (R01 Clinical Trial Not Allowed)" & RFA-HG-21-002, “Technology Development for Single-Molecule Protein Sequencing (R21 Clinical Trial Not Allowed)"

Notice Number:

NOT-HG-23-013

Key Dates

Release Date:

November 18, 2022

Related Announcements

RFA-HG-21-001- Technology Development for Single-Molecule Protein Sequencing (R01 Clinical Trial not allowed)

RFA-HG-21-002- Technology Development for Single-Molecule Protein Sequencing (R21 Clinical Trial not allowed)

Issued by

National Human Genome Research Institute (NHGRI)

Purpose

The purpose of this Notice is to inform the extramural community of the early expiration of:

RFA-HG-21-001-Technology Development for Single-Molecule Protein Sequencing (R01 Clinical Trial not allowed) and
RFA-HG-21-002-Technology Development for Single-Molecule Protein Sequencing (R21 Clinical Trial not allowed, effective immediately.

Applicants who wish to conduct pilot and research projects related to the topics in these RFAs may consider applying under the currently active parent R01 and parent R21 Funding Opportunity Announcements.

The expiration date in Part.1 Overview Information, Key Dates section of these two RFAs currently reads: Expiration Date: June 16, 2023.

The expiration date in Part.1 Overview Information, Key Dates section of these two RFAs has been modified to read: Expiration Date: December 1, 2022.

All other aspects of these two RFAs remain unchanged.

Inquiries

Please direct all inquiries to:

Temesgen D. Fufa, Ph.D.
National Human Genome Research Institute (NHGRI)
Telephone: (301) 480-2280
Email: [email protected]